Dupilumab De-escalation in Pediatric Atopic Dermatitis
NCT06116526
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Atopic Dermatitis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 1 year to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Johns Hopkins University
- Last updated on ClinicalTrials.gov
- April 20, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Maryland · 1
- Johns Hopkins Univerisity · Baltimore, MD
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.